Biotech IV Monitor

ARQT — Arcutis Biotherapeutics Inc.

$3.4B market cap · 1 upcoming readout tracked

Clinical trial readout dates for Arcutis Biotherapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2028.

Next readoutApril 2028in ~17 months
Upcoming readouts11 Phase 3
Market cap$3.4B
Cash & investments$259Mas of Sep 30, 2026
Recent 8-K filings2latest 2026-11-04

Upcoming readouts

Phase 3 Roflumilast Cream 0.3%
Atopic Dermatitis; Atopic Dermatitis (AD) · NCT07916480
April 2028
Recruiting

Cash position

Arcutis Biotherapeutics Inc. reported $259M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). It reported net income of $9M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-04
8-K Reg FD Disclosure — often a data announcement2026-10-28

Companies working on similar indications

Discussion

No messages yet. If you follow ARQT, you can start the conversation.
Track ARQT in real time
See live implied volatility for ARQT and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ARQT
Contact — questions or corrections about ARQT: dukeupt@gmail.com